Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): Study protocol for a randomized phase II trial

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Decaestecker, Karel ^a   De Meerleer, Gert ^a   Ameye, Filip ^b   Fonteyne, Valerie ^a   Lambert, Bieke ^a   Joniau, Steven ^c   Delrue, Louke ^a   Billiet, Ignace ^b   Duthoy, Wim ^b   Junius, Sarah ^b   Huysse, Wouter ^a   Lumen, Nicolaas ^a   Ost, Piet ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b Department of Radiotherapy Ghent University Hospital ^*  (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Active surveillance; Androgen deprivation therapy; Oligometastases; Prostate cancer; Quality of life; Salvage lymph node dissection; Salvage treatment; Stereotactic body radiotherapy; Survival

Indexed keywords

CHOLINE C 11; PROSTATE SPECIFIC ANTIGEN;

ADULT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER RECURRENCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONE BEAM COMPUTED TOMOGRAPHY; CONTROLLED STUDY; EXTENDED PELVIC LYMPH NODE DISSECTION; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MALE; METASTASIS; METASTASIS DIRECTED THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; OLIGOMETASTASIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; STEREOTACTIC BODY RADIATION THERAPY; AGED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; HEALTH SURVEY; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOSURGERY; YOUNG ADULT;

ADULT; AGED; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PUBLIC HEALTH SURVEILLANCE; QUALITY OF LIFE; RADIOSURGERY; YOUNG ADULT;

EID: 84908093419     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-671     Document Type: Article

References (26)

1. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N. EAU guidelines on prostate cancer. part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014, 65(2):467-479. 10.1016/j.eururo.2013.11.002, 24321502.
2. Abrahamsson PA. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 2010, 57(1):49-59. 10.1016/j.eururo.2009.07.049, 19683858.
3. Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 2009, 115(11):2388-2399. 10.1002/cncr.24283, 19399748.
4. Decaestecker K, De Meerleer G, Lambert B, Delrue L, Fonteyne V, Claeys T, De Vos F, Huysse W, Ost P. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol 2014, in press.
5. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A. EAU guidelines on prostate cancer. part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011, 59(4):572-583. 10.1016/j.eururo.2011.01.025, 21315502.
6. Umbehr MH, Muntener M, Hany T, Sulser T, Bachmann LM. The role of 11C-choline and 18 F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol 2013, 64(1):106-117. 10.1016/j.eururo.2013.04.019, 23628493.
7. Wondergem M, van der Zant FM, van der Ploeg T, Knol RJ. A literature review of 18 F-fluoride PET/CT and 18 F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer. Nucl Med Commun 2013, 34(10):935-945. 10.1097/MNM.0b013e328364918a, 23903557.
8. Berkovic P, De Meerleer G, Delrue L, Lambert B, Fonteyne V, Lumen N, Decaestecker K, Villeirs G, Vuye P, Ost P. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer 2013, 11(1):27-32. 10.1016/j.clgc.2012.08.003, 23010414.
9. Suardi N, Gandaglia G, Gallina A, Di Trapani E, Scattoni V, Vizziello D, Cucchiara V, Bertini R, Colombo R, Picchio M, Giovacchini G, Montorsi F, Briganti A. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol 2014, doi:10.1016/j.eururo.2014.02.011.
10. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M, . Prostate Cancer Clinical Trials Working Group Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008, 26(7):1148-1159. 10.1200/JCO.2007.12.4487, 4010133, 18309951, Prostate Cancer Clinical Trials Working Group.
11. Bottomley A, Flechtner H, Efficace F, Vanvoorden V, Coens C, Therasse P, Velikova G, Blazeby J, Greimel E, . European Organisation for Research and Treatment of Cancer Health related quality of life outcomes in cancer clinical trials. Eur J Cancer 2005, 41(12):1697-1709. 10.1016/j.ejca.2005.05.007, 16043345, European Organisation for Research and Treatment of Cancer.
12. EuroQol Group EuroQol--a new facility for the measurement of health-related quality of life. the EuroQol Group. Health Policy 1990, 16(3):199-208. EuroQol Group.
13. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13(3):176-181. 10.1016/S1053-4296(03)00031-6, 12903007.
14. Mitropoulos D, Artibani W, Graefen M, Remzi M, Roupret M, Truss M. Reporting and grading of complications after urologic surgical procedures: an ad hoc EAU guidelines panel assessment and recommendations. Eur Urol 2012, 61(2):341-349. 10.1016/j.eururo.2011.10.033, 22074761.
15. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(2):228-247. 10.1016/j.ejca.2008.10.026, 19097774.
16. Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, Rouviere O, Logager V, Futterer JJ, . European Society of Urogenital Radiology ESUR prostate MR guidelines 2012. Eur Radiol 2012, 22(4):746-757. 10.1007/s00330-011-2377-y, 3297750, 22322308, European Society of Urogenital Radiology.
17. Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, Keall P, Lovelock M, Meeks S, Papiez L, Purdie T, Sadagopan R, Schell MC, Salter B, Schlesinger DJ, Shiu AS, Solberg T, Song DY, Stieber V, Timmerman R, Tome WA, Verellen D, Wang L, Yin FF. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 2010, 37(8):4078-4101. 10.1118/1.3438081, 20879569.
18. Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, Villaflor VM, Stadler WM, Hoffman PC, Cohen EE, Connell PP, Haraf DJ, Vokes EE, Hellman S, Weichselbaum RR. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer 2012, 118(11):2962-2970. 10.1002/cncr.26611, 22020702.
19. Casamassima F, Masi L, Menichelli C, Bonucci I, Casamassima E, Lazzeri M, Gulisano M, Aterini S. Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori 2011, 97(1):49-55.
20. Bedford JL, Lee YK, Wai P, South CP, Warrington AP. Evaluation of the Delta4 phantom for IMRT and VMAT verification. Phys Med Biol 2009, 54(9):N167-N176. 10.1088/0031-9155/54/9/N04, 19384007.
21. Rubinstein LV, Korn EL, Freidlin B, Hunsberger S, Ivy SP, Smith MA. Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 2005, 23(28):7199-7206. 10.1200/JCO.2005.01.149, 16192604.
22. Palma DA, Haasbeek CJ, Rodrigues GB, Dahele M, Lock M, Yaremko B, Olson R, Liu M, Panarotto J, Griffioen GH, Gaede S, Slotman B, Senan S. Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial. BMC Cancer 2012, 12:305. 10.1186/1471-2407-12-305, 3433376, 22823994.
23. Palmbos PL, Hussain M. Non-castrate metastatic prostate cancer: have the treatment options changed?. Semin Oncol 2013, 40(3):337-346. 10.1053/j.seminoncol.2013.04.007, 23806498.
24. Jilg CA, Rischke HC, Reske SN, Henne K, Grosu AL, Weber W, Drendel V, Schwardt M, Jandausch A, Schultze-Seemann W. Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. J Urol 2012, 188(6):2190-2197. 10.1016/j.juro.2012.08.041, 23083862.
25. Schick U, Jorcano S, Nouet P, Rouzaud M, Vees H, Zilli T, Ratib O, Weber DC, Miralbell R. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol 2013, 52(8):1622-1628. 10.3109/0284186X.2013.764010, 23544357.
26. Jereczek-Fossa BA, Beltramo G, Fariselli L, Fodor C, Santoro L, Vavassori A, Zerini D, Gherardi F, Ascione C, Bossi-Zanetti I, Mauro R, Bregantin A, Bianchi LC, De Cobelli O, Orecchia R. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 2012, 82(2):889-897. 10.1016/j.ijrobp.2010.11.031, 21277113.